Details About Generic Salt ::  Glimepir

Main Medicine Class:: Antidiabetic,Sulfonylurea   

(GLIE-meh-pie-ride)

Amaryl

Class: Antidiabetic/Sulfonylurea

 

Drugs Class ::

 Action Decreases blood glucose by stimulating insulin release from pancreas. May also decrease hepatic glucose production as well as increase sensitivity to insulin.

Indications for Drugs ::

 Indications Adjunct to diet and exercise in type II diabetics whose hyperglycemia cannot be controlled by diet and exercise alone; in combination with insulin for type II diabetics with secondary failure to oral sulfonylureas.

Drug Dose ::

 Route/Dosage

ADULTS: PO 1 to 2 mg qd with breakfast or the first main meal of the day. Increase by 1 to 2 mg/dose. Titrate at 1 to 2 week intervals based on blood glucose response. Maintenance: 1 and 4 mg daily (maximum 8 mg/day). Combination therapy with insulin is appropriate for secondary failure to oral sulfonylureas. The same dosing recommendations apply.

Contraindication ::

 Contraindications Hypersensitivity to sulfonylureas; diabetic ketoacidosis with or without coma.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Insulin is recommended to maintain blood glucose levels during pregnancy. Prolonged severe neonatal hypoglycemia can occur if sulfonylureas are administered at time of delivery. Lactation: Undetermined. Children: Safety and efficacy not established. Elderly and debilitated patients: Increased risk for development of hypoglycemia. Hypoglycemia may be difficult to detect in elderly patients. Hepatic and renal impairment: Use with caution; lower doses may be adequate.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CV: Although issue is controversial, oral sulfonylureas may have increased risk of cardiovascular morbidity when compared with patients treated with diet alone. CNS: Dizziness. DERM: Allergic skin reactions (pruritus, erythema, urticaria, morbilliform or maculopapular rash); porphyria cutanea tarda; photosensitivity. EENT: Blurred vision. GI: Nausea; vomiting; gastrointestinal pain; diarrhea. HEMA: Leukopenia; agranulocytosis; thrombocytopenia; hemolytic anemia; aplastic anemia; pancytopenia. HEPA: Cholestatic jaundice; elevated liver function tests. META: Hypoglycemia. OTHER: Headache; asthenia; hyponatremia with or without syndrome of inappropriate antidiuretic hormone (SIADH).

Drug Mode of Action ::  

 Action Decreases blood glucose by stimulating insulin release from pancreas. May also decrease hepatic glucose production as well as increase sensitivity to insulin.

Drug Interactions ::

 Interactions

Alcohol: Produces disulfiram-like reaction (facial flushing, headache, breathlessness). Chloramphenicol, clofibrate, fenfluramine, histamine H2 antagonists, miconazole, monoamine oxidase inhibitors, probenecid, salicylates, sulfinpyrazone, sulfonamides, tricyclic antidepressants, urinary acidifiers: May increase hypoglycemic effect. Betablockers, cholestyramine, diazoxide, rifampin, thiazide diuretics, urinary alkalinizers: May decrease hypoglycemic effect.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history.
• Assess patient for evidence of hypoglycemic reaction; hypoglycemia may be difficult to detect in the elderly.
• Note hepatic or renal impairment.

OVERDOSAGE: SIGNS & SYMPTOMS   Hypoglycemia, tingling of lips and tongue, hunger, nausea, lethargy, tachycardia, sweating, confusion, tremor, convulsions, stupor, coma

Drug Storage/Management ::

 Administration/Storage

• Give the dose with breakfast or the first meal of the day.
• Store at room temperature.

Drug Notes ::

 Patient/Family Education

• Instruct patient in signs, symptoms, and treatment of hypoglycemic reaction.
• Review dietary and exercise guidelines for diabetes with patient.
• Instruct patient to take drug with breakfast.
• Teach patient to self-monitor urine or blood glucose.
• Instruct patient to inform all health careproviders involved in his/her care that he/she is taking this drug and to carry medical identification (eg, Medi-Alert bracelet).
• Instruct patient to notify health careprovider if symptoms of hypoglycemia occur (fatigue, excessive hunger, profuse sweating, numbness of extremities) or if blood glucose is below 60 mg/dl.
• Tell patient to notify health careprovider if symptoms of hyperglycemia occur (excessive thirst or urination, urinary glucose or ketones).
• Instruct patient to report these symptoms to health careprovider: Nausea, vomiting, diarrhea, heartburn, sore throat, rash, unusual bleeding or bruising, or other physical complaints.
• Advise patient not to take any medication, including otc, or alcohol without consulting health careprovider.
• Advise patient to avoid exposure to sunlight or sunlamps and to use sunscreen or wear protective clothing to avoid photosensitivity reaction.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.